LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases ...
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and ...
BEIJING, Nov. 10, 2025 /PRNewswire/ -- The Honor of Kings King Pro League (KPL) 2025 Grand Finals, hosted by Tencent and organized by Hero Esports, came to a triumphant close at Beijing's iconic ...
Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing Phase 1 ...
VNA and KPL serve not only as communication bridges between the two Parties, States, and peoples but also as key forces in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback